These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 26628579

  • 1. Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry.
    Glintborg B, Højgaard P, Lund Hetland M, Steen Krogh N, Kollerup G, Jensen J, Chrysidis S, Jensen Hansen IM, Holland-Fischer M, Højland Hansen T, Nilsson C, Espesen J, Nordin H, Rasmussen Loft AG, Pelck R, Lorenzen T, Flejsborg Oeftiger S, Unger B, Jaeger F, Mosborg Petersen P, Rasmussen C, Dreyer L.
    Rheumatology (Oxford); 2016 Apr; 55(4):659-68. PubMed ID: 26628579
    [Abstract] [Full Text] [Related]

  • 2. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry.
    Højgaard P, Glintborg B, Hetland ML, Hansen TH, Lage-Hansen PR, Petersen MH, Holland-Fischer M, Nilsson C, Loft AG, Andersen BN, Adelsten T, Jensen J, Omerovic E, Christensen R, Tarp U, Østgård R, Dreyer L.
    Ann Rheum Dis; 2015 Dec; 74(12):2130-6. PubMed ID: 25063827
    [Abstract] [Full Text] [Related]

  • 3. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
    Glintborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen PM, Hetland ML.
    Ann Rheum Dis; 2013 Jul; 72(7):1149-55. PubMed ID: 22941767
    [Abstract] [Full Text] [Related]

  • 4. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B, Sørensen IJ, Østergaard M, Dreyer L, Mohamoud AA, Krogh NS, Hendricks O, Andersen LS, Raun JL, Kowalski MR, Danielsen L, Pelck R, Nordin H, Pedersen JK, Kraus DG, Christensen SR, Hansen IM, Esbesen J, Schlemmer A, Loft AG, Al Chaer N, Salomonsen L, Hetland ML.
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [Abstract] [Full Text] [Related]

  • 5. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
    Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML.
    Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
    [Abstract] [Full Text] [Related]

  • 6. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
    Ciurea A, Scherer A, Weber U, Exer P, Bernhard J, Tamborrini G, Riek M, Müller RB, Weiss B, Nissen MJ, Kissling R, Michel BA, Finckh A, Rheumatologists of Swiss Clinical Quality Management Program for Axial Spondyloarthritis.
    Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
    [Abstract] [Full Text] [Related]

  • 7. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
    Højgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L.
    Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
    [Abstract] [Full Text] [Related]

  • 8. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
    Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG, Lindegaard HM, Holland-Fischer M, Nordin H, Jensen DV, Olsen CH, Hetland ML.
    Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
    [Abstract] [Full Text] [Related]

  • 9. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M, All Departments of Rheumatology in Denmark.
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [Abstract] [Full Text] [Related]

  • 10. Extremely poor patient-reported outcomes are associated with lack of clinical response and decreased retention rate of tumour necrosis factor inhibitor treatment in patients with axial spondyloarthritis.
    Krabbe S, Glintborg B, Østergaard M, Hetland ML.
    Scand J Rheumatol; 2019 Mar; 48(2):128-132. PubMed ID: 30102111
    [Abstract] [Full Text] [Related]

  • 11. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y, Park S, Kim HS.
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [Abstract] [Full Text] [Related]

  • 12. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
    Hellgren K, Dreyer L, Arkema EV, Glintborg B, Jacobsson LT, Kristensen LE, Feltelius N, Hetland ML, Askling J, ARTIS Study Group, For the DANBIO Study Group.
    Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
    [Abstract] [Full Text] [Related]

  • 13. Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry.
    Ornbjerg LM, Ostergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Ringsdal VS, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Dencker D, Hansen A, Andersen AR, Hetland ML.
    Ann Rheum Dis; 2013 Jan; 72(1):57-63. PubMed ID: 22532636
    [Abstract] [Full Text] [Related]

  • 14. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J, Flipo RM, Philippe P, Bera-Louville A, Béhal H, Wibaux C, Paccou J.
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [Abstract] [Full Text] [Related]

  • 15. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
    Lie E, Kristensen LE, Forsblad-d'Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT, ARTIS Study Group.
    Ann Rheum Dis; 2015 Jun; 74(6):970-8. PubMed ID: 25710471
    [Abstract] [Full Text] [Related]

  • 16. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.
    Glintborg B, Gudbjornsson B, Krogh NS, Omerovic E, Manilo N, Holland-Fischer M, Lindegaard HM, Loft AG, Nordin H, Johnsen L, Oeftiger SF, Hansen A, Rasmussen C, Grondal G, Geirsson AJ, Hetland ML.
    Rheumatology (Oxford); 2014 Nov; 53(11):2100-9. PubMed ID: 24939677
    [Abstract] [Full Text] [Related]

  • 17. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
    Lie E, Lindström U, Zverkova-Sandström T, Olsen IC, Forsblad-d'Elia H, Askling J, Kapetanovic MC, Kristensen LE, Jacobsson LTH.
    Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
    [Abstract] [Full Text] [Related]

  • 18. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
    Capkin E, Karkucak M, Cosar AM, Ak E, Karaca A, Gokmen F, Budak BS, Tosun M.
    Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
    [Abstract] [Full Text] [Related]

  • 19. Smoking did not modify the effects of anti-TNF treatment on health-related quality of life among Australian ankylosing spondylitis patients.
    Kydd AS, Chen JS, Makovey J, Chand V, Henderson L, Buchbinder R, Lassere M, March LM.
    Rheumatology (Oxford); 2015 Feb; 54(2):310-7. PubMed ID: 25173348
    [Abstract] [Full Text] [Related]

  • 20. Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.
    van Weely SF, Kneepkens EL, Nurmohamed MT, Dekker J, van der Horst-Bruinsma IE.
    Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1522-9. PubMed ID: 26881893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.